Jonathan Young, Chief Operating Officer at Akero Therapeutics, Inc. (AKRO), sold 15,239 shares at $45.78 ($705K) on 2025-09-02, disclosed to the SEC on 2025-09-04.
Scheduled sale ($705k) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.78 | 9,700 | $444K | 63.0% |
| 2 | $47.14 | 2,739 | $129K | 18.3% |
| 3 | $47.14 | 2,739 | $129K | 18.3% |
| 4 | $47.58 | 61 | $3K | 0.4% |
| Total | $46.28 avg | 15,239 | $705K | 100% |
| Filing → |
| AKRO | SELL | 2025-08-13 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $159K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $269K | — | Filing → |